Katie Dahlstrom
Directeur Technique/Scientifique/R&D chez THESEUS PHARMACEUTICALS, INC.
Profil
Katie Dahlstrom is currently the Vice President-Clinical Development Operations at Theseus Pharmaceuticals, Inc. Previously, she worked as the Senior Director-Clinical Operations at Agios Pharmaceuticals, Inc. She completed her undergraduate degree at Stonehill College, Inc. and her graduate degree at Boston University School of Medicine.
Postes actifs de Katie Dahlstrom
| Sociétés | Poste | Début |
|---|---|---|
| THESEUS PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | - |
Anciens postes connus de Katie Dahlstrom
| Sociétés | Poste | Fin |
|---|---|---|
| AGIOS PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | - |
Formation de Katie Dahlstrom
| Stonehill College, Inc. | Undergraduate Degree |
| Boston University School of Medicine | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AGIOS PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Theseus Pharmaceuticals, Inc.
 Theseus Pharmaceuticals, Inc. BiotechnologyHealth Technology Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. It focuses on the discovery, development and commercialization of transformative targeted therapies. The company was founded by William C. Shakespeare, David C. Dalgarno, Iain D. Dukes, Wei Sheng Huang and Victor M. Rivera on December 29, 2017 and is headquartered in Cambridge, MA. | Health Technology |